Johnson & Johnson Forecast, price target & analysts
Johnson & Johnson Target price 2025 - Analyst rating & recommendation
Johnson & Johnson Classifications & Recommendation:
Johnson & Johnson Price Target
| Target Price | $179.90 |
| Price | $191.17 |
| Deviation | 5.90% |
| Number of Estimates | 28 |
| 28 Analysts have issued a price target Johnson & Johnson 2026 . The average Johnson & Johnson target price is $179.90. This is 5.90% lower than the current stock price. The highest price target is $216.30 13.15% , the lowest is $156.55 18.11% . | |
| A rating was issued by 31 analysts: 17 Analysts recommend Johnson & Johnson to buy, 14 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Johnson & Johnson stock has an average upside potential 2026 of 5.90% . Most analysts recommend the Johnson & Johnson stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
26 Analysts have issued a sales forecast Johnson & Johnson 2025 . The average Johnson & Johnson sales estimate is $94.3b . This is 4.08% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $98.5b 8.65% , the lowest is $90.7b 0.07% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $88.8b | 4.30% |
|---|---|---|
| 2025 | $94.3b | 6.19% |
| 2026 | $98.6b | 4.58% |
| 2027 | $103b | 4.50% |
| 2028 | $108b | 4.39% |
| 2029 | $113b | 4.80% |
| 2030 | $119b | 5.82% |
| 2031 | $119b | 0.09% |
| 2032 | $120b | 0.62% |
19 Analysts have issued an Johnson & Johnson EBITDA forecast 2025. The average Johnson & Johnson EBITDA estimate is $35.1b . This is 14.33% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $40.1b 30.64% , the lowest is $29.9b 2.62% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $30.8b | 2.81% |
|---|---|---|
| 2025 | $35.1b | 13.67% |
| 2026 | $36.8b | 4.99% |
| 2027 | $39.0b | 6.05% |
| 2028 | $38.7b | 0.95% |
| 2029 | $40.9b | 5.68% |
EBITDA Margin
| 2024 | 34.72% | 6.82% |
|---|---|---|
| 2025 | 37.17% | 7.04% |
| 2026 | 37.31% | 0.38% |
| 2027 | 37.87% | 1.50% |
| 2028 | 35.93% | 5.12% |
| 2029 | 36.24% | 0.86% |
27 Johnson & Johnson Analysts have issued a net profit forecast 2025. The average Johnson & Johnson net profit estimate is $26.4b . This is 16.50% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $27.9b 23.12% , the lowest is $25.1b 10.75% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $14.1b | 59.99% |
|---|---|---|
| 2025 | $26.4b | 87.69% |
| 2026 | $27.6b | 4.59% |
| 2027 | $29.4b | 6.40% |
| 2028 | $30.5b | 3.92% |
| 2029 | $32.9b | 7.70% |
| 2030 | $36.3b | 10.36% |
| 2031 | $37.0b | 1.91% |
| 2032 | $37.6b | 1.73% |
Net Margin
| 2024 | 15.84% | 61.64% |
|---|---|---|
| 2025 | 27.99% | 76.75% |
| 2026 | 27.99% | 0.00% |
| 2027 | 28.50% | 1.82% |
| 2028 | 28.37% | 0.46% |
| 2029 | 29.16% | 2.78% |
| 2030 | 30.41% | 4.29% |
| 2031 | 30.96% | 1.81% |
| 2032 | 31.30% | 1.10% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
27 Analysts have issued a Johnson & Johnson forecast for earnings per share. The average Johnson & Johnson EPS is $10.97 . This is 17.33% higher than earnings per share in the financial year 2024. The highest EPS forecast is $11.59 23.96% , the lowest is $10.43 11.55% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $5.79 | 57.80% |
|---|---|---|
| 2025 | $10.97 | 89.46% |
| 2026 | $11.47 | 4.56% |
| 2027 | $12.21 | 6.45% |
| 2028 | $12.69 | 3.93% |
| 2029 | $13.66 | 7.64% |
| 2030 | $15.08 | 10.40% |
| 2031 | $15.37 | 1.92% |
| 2032 | $15.63 | 1.69% |
P/E ratio
| Current | 20.41 | 23.64% |
|---|---|---|
| 2025 | 17.40 | 14.76% |
| 2026 | 16.63 | 4.43% |
| 2027 | 15.63 | 6.01% |
| 2028 | 15.04 | 3.77% |
| 2029 | 13.97 | 7.11% |
| 2030 | 12.66 | 9.38% |
| 2031 | 12.42 | 1.90% |
| 2032 | 12.21 | 1.69% |
Based on analysts' sales estimates for 2025, the Johnson & Johnson stock is valued at an EV/Sales of 5.21 and an P/S ratio of 4.87 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 5.42 | 17.57% |
|---|---|---|
| 2025 | 5.21 | 3.86% |
| 2026 | 4.98 | 4.38% |
| 2027 | 4.77 | 4.30% |
| 2028 | 4.57 | 4.21% |
| 2029 | 4.36 | 4.58% |
| 2030 | 4.12 | 5.50% |
| 2031 | 4.11 | 0.09% |
| 2032 | 4.09 | 0.62% |
P/S ratio
| Current | 5.07 | 14.43% |
|---|---|---|
| 2025 | 4.87 | 3.92% |
| 2026 | 4.66 | 4.38% |
| 2027 | 4.46 | 4.31% |
| 2028 | 4.27 | 4.21% |
| 2029 | 4.08 | 4.58% |
| 2030 | 3.85 | 5.50% |
| 2031 | 3.85 | 0.09% |
| 2032 | 3.82 | 0.62% |
Johnson & Johnson...
Current Johnson & Johnson Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 10 2025 |
| Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Oct 09 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 07 2025 |
| Bernstein |
Market Perform
➜
Market Perform
|
Unchanged | Oct 06 2025 |
| B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Oct 03 2025 |
| Wells Fargo |
Equal-Weight
➜
Overweight
|
Upgrade | Oct 03 2025 |
| Guggenheim |
Neutral
➜
Buy
|
Upgrade | Sep 23 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 10 2025 |
|
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Oct 09 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 07 2025 |
|
Unchanged
Bernstein:
Market Perform
➜
Market Perform
|
Oct 06 2025 |
|
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Oct 03 2025 |
|
Upgrade
Wells Fargo:
Equal-Weight
➜
Overweight
|
Oct 03 2025 |
|
Upgrade
Guggenheim:
Neutral
➜
Buy
|
Sep 23 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
